Study Evaluating Bifeprunox in Patients With Schizophrenia.

• Status: Terminated
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

1. Outpatients who have successfully completed Wyeth study 3168A1-313.

2. A signed and dated informed consent form for this study.

3. No major protocol violations in the previous study.

Exclusion Criteria:

1. Clinically important abnormalities in the preceding short-term study that have not resolved.

2. Use of prohibited treatments in the preceding short-term study.

3. Meeting any exclusion criteria in the preceding short-term study